Brief: ExpreS2ion Updates On Its Pipeline Outlook, Including For Covid-19 And HER2 Breast Cancer Projects

ExpreS2ion Biotech Holding AB

16/03/2021 07:04

March 16 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * EXPRES2ION UPDATES ON ITS PIPELINE OUTLOOK, INCLUDING FOR
COVID-19 AND HER2 BREAST CANCER PROJECTS
    * ABNCOV2 COVID-19 VACCINE: INITIAL SAFETY DATA FROM STUDY
IS
EXPECTED IN Q1 2021 AND WILL BE ANNOUNCED IN APRIL
    * ABNCOV2 COVID-19 VACCINE: HEADLINE RESULTS FROM STUDY ARE
EXPECTED BY END OF JUNE 2021
    * ES2B-C001 HER2-CVLP BREAST CANCER VACCINE: CLINICAL
PROGRAM IS
EXPECTED TO START IN 2022 WITH GMP MANUFACTURING OF ES2B-C001
    * ES2B-C001 HER2-CVLP BREAST CANCER VACCINE: PRECLINICAL
PROOF OF
CONCEPT DATA FOR ES2B-C001 IS EXPECTED AT END OF 2021
    * EU HORIZON 2020-FUNDED INFLUENZA VACCINE PROGRAM:
PRECLINICAL
ACTIVITIES ARE PLANNED TO BE INITIATED LATER IN 2021

Source text for Eikon:  ID:nWkr7t3QM3 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))